Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients. © 2011 Elsevier Ltd.
Fabbiani, M., Di Giambenedetto, S., Sali, M., Farina, S., Sansonetti, P., Tamburrini, E., Verme, L. Z. D., Delogu, G., De Luca, A., Kelvin, D., Cauda, R., Fadda, G., Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients, <<VACCINE>>, 2011; 29 (16): 2836-2839. [doi:10.1016/j.vaccine.2011.02.020] [http://hdl.handle.net/10807/104313]
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
Fabbiani, MassimilianoPrimo
;Di Giambenedetto, SimonaSecondo
;Sali, Michela
;Sansonetti, Paola;Tamburrini, Enrica;Delogu, Giovanni;De Luca, Andrea;Cauda, RobertoPenultimo
;Fadda, GiovanniUltimo
2011
Abstract
Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients. © 2011 Elsevier Ltd.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
